Category: News & Events

Research Hotspots and Trends in Home-Based Cardiac Rehabilitation: A Bibliometric Visualization Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This research was aimed at determining research hotspots and major topics in the field of international home-based cardiac rehabilitation (HBCR) over the past 20 years and exploring future trends in HBCR. A total of 757 research articles from 2002 to 2022, with themes of home-based cardiac rehabilitation, were included in the core collection database of Web of Science. CiteSpace software was used for literature metrology and visualization analysis.

The total number of research articles on HBCR is increasing.

Research hotspots in HBCR include the effectiveness of rehabilitation after coronary heart disease or heart failure; quality of life; mental health; and home rehabilitation after COVID-19.

Research trends in HBCR include wearable intelligent technology; telerehabilitation; lifestyle interventions; and home-based rehabilitation prescriptions for exercise, nutrition, psychology and continuous management.

The effects of HBCR have been continuously verified. Research has focused primarily on secondary prevention and rehabilitation after coronary heart disease and heart failure. More attention must be paid to improving patients’ quality of life by HBCR. Telerehabilitation based on wearable intelligent technology, home-based lifestyle interventions and continuous management are future trends of HBCR development.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0045

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Li Jianchao, Zhao Yu and Tao Chunjing et al. Research Hotspots and Trends in Home-Based Cardiac Rehabilitation: A Bibliometric Visualization Analysis. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0045

Loading

Advances in Left Bundle Branch Pacing: Definition, Evaluation, and Applications

Announcing a new article publication for Cardiovascular Innovations and Applications journal.     Left bundle branch pacing (LBBP) emerged as a new physiological pacing strategy during the past several years. Recent observational studies have demonstrated the advantages of LBBP, including a high success rate, stable pacing parameters, and excellent clinical benefits. Widespread adoption of LBBP will depend on improvements in device/lead technology and further verification of its efficacy in large randomized clinical trials.

This article summarizes recent advancements in LBBP, including the definition and evaluation of left bundle branch capture, LBBP applications, and future directions in this growing field.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0047

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiaxing Zeng, Siyuan Xue and Fengwei Zou et al. Advances in Left Bundle Branch Pacing: Definition, Evaluation, and Applications. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0047

Loading

Phrenic Nerve Injury During Ablation of Atrial Fibrillation: Mechanisms, Clinical Features, Prognosis, and Prevention Methods

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Atrial fibrillation ablation procedures have become a focus of research among electrophysiologists, with the aim of increasing success rates while minimizing complications. One major concern is phrenic nerve injury (PNI). Despite advancements in ablation strategies, equipment, and monitoring methods, the incidence of PNI during these procedures remains substantial, particularly during cryoballoon ablation, which has a reported PNI incidence of 3.5%.

This article examines recent studies, to provide a comprehensive overview of PNI mechanisms, clinical features, prognosis, and methods for prevention during ablation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0050

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xinmeng Liu, Rong Lin and Xiaodong Peng et al. Phrenic Nerve Injury During Ablation of Atrial Fibrillation: Mechanisms, Clinical Features, Prognosis, and Prevention Methods. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0050

Loading

Transcatheter Aortic Valve Replacement for Aortic Regurgitation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Transcatheter aortic valve replacement (TAVR) is currently a widely used option for patients with severe symptomatic aortic stenosis with high to low surgical risk. However, aortic regurgitation (AR) remains an “off-label” indication for TAVR, particularly for patients with mild or absent leaflet calcification or aortic annulus dimensions beyond the size of the bioprosthesis, which increase the risk of dislocation. With advances in transcatheter heart valve devices, the safety and efficacy of TAVR in treating patients with severe pure native AR has gained acceptance.

This article examines current evidence and clinical practice, and presents technological advancements in devices for AR.

Read full article at Scienceopen: https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0033

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Ran Liu, Zhaolin Fu and Jing Yao et al. Transcatheter Aortic Valve Replacement for Aortic Regurgitation – A Review. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0033

Loading

Post-Translational Modification of Drp1 is a Promising Target for Treating Cardiovascular Diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Mitochondria are essential for cell growth, fission, differentiation, and survival, particularly in undivided cells with high energy requirements, such as cardiomyocytes. The morphology and position of mitochondria change with the activity of mitochondrial fission proteins and mitochondrial fusion proteins. These regulatory mechanisms substantially affect cardiomyocyte energy supply and normal function. In mitochondrial fission, dynamin-related protein 1 (Drp1) is involved in the separation and degradation of damaged mitochondria, and accurately regulates mitochondrial renewal and number. Recent studies have revealed a variety of post-translational modification (PTMs) of Drp1, including phosphorylation, SUMOylation, acetylation, O-GlcNAcylation, and S-sulfhydration. These modifications ensure that Drp1 continues to function normally in various signaling pathways, by modulating its activity, stability, and subcellular localization.

This article provides an overview of the relationship between Drp1 PTMs and cardiovascular diseases such as heart failure, myocardial infarction, and myocardial ischemia-reperfusion, and describes how these modifications can be targeted and regulated, to help guide cardiovascular disease treatment.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0043

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yingjie Ji, Han Zhou and Chen Yang et al. Post-Translational Modification of Drp1 is a Promising Target for Treating Cardiovascular Diseases. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0043

Loading

Sex Differences in Transcatheter Structural Heart Disease Interventions: How Much Do We Know?

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  The number of structural heart disease interventions has greatly increased in the past decade. Moreover, interest in the sex-specific outcomes of various cardiovascular conditions and procedures has increased. The authors of this article discuss the sex differences in the clinical profiles and outcomes of patients undergoing the most commonly performed structural procedures: transcatheter aortic valve replacement, transcatheter edge to edge repair of the mitral and tricuspid valve, transcatheter pulmonary valve replacement, patent foramen ovale closure and left atrial appendage occlusion. The potential reasons for these differences are reviewed and the authors emphasize the importance of increasing the representation of women in randomized clinical trials, to understand these differences and support the application of these cutting-edge technologies.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0049

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Lina Ya’Qoub, Jelena Arnautovic and Nadeen N. Faza et al. Sex Differences in Transcatheter Structural Heart Disease Interventions: How Much Do We Know? CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0049

Loading

Cardiovascular Innovations and Applications Achieves New Milestone

The Co-Editors-in-Chief of Cardiovascular Innovations and Applications (CVIA), Jamie B. Conti, University of Florida, Gainesville, FL, USA and Jianzeng Dong, Beijing Anzhen Hospital, Capital Medical University, Beijing, China are pleased to announce the inclusion of CVIA in the 2023 Journal Citation Reports (JCR) from Clarivate.

CVIA, received its first Journal Impact Factor (JIF) of 0.5 this year after being launched in 2016 and accepted into Emerging Sources Citation Index (ESCI) in 2018. 

About CVIA

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA  as an open access journal offers high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving of author fees.  

The journal welcomes the following article types:

  • Editorials
  • Original Research
  • Review Articles
  • Commentaries
  • Case Reports
  • Case Studies
  • Methodology papers related to clinical trials
  • Letters to the Editor

Benefits of choosing CVIA for your research

  • CVIA is a platinum open access journal which means that your paper is available to anyone in the world to download for free directly from the ScienceOpen website.
  • No Author submission or article processing charges.
  • Authors can retain the copyright to their article.
  • Fast peer review.
  • Fast publication online after article acceptance.
  • Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • Professional/global marketing/promotion of your articles. Articles are:
  • Sent to clinicians and researchers in the cardiovascular community through email alerts;
  • Promoted to the Journal followers on Twitter and Facebook;
  • Distributed to news outlets through press releases.

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen  https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Articles of interest include:

Machine Learning Methods in Real-World Studies of Cardiovascular Disease

Experience in Application of a Three-Dimensional Pulsed Field Ablation System Integrating Mapping and Ablation

Association between Percentage of Neutrophils at Admission and in-Hospital Events in Patients ≥75 Years of Age with Acute Coronary Syndrome

Spontaneous Heparin-Induced Thrombocytopenia Presenting as Concomitant Bilateral Cerebrovascular Infarction and Acute Coronary Syndrome

Advances in Renal Denervation in the Treatment of Hypertension

Elevated Monocyte to High-density Lipoprotein Ratio Is a Risk Factor for New-onset Atrial Fibrillation after Off-pump Coronary Revascularization

The Neutrophil/Lymphocyte Ratio is Associated with Different Stages of Development of Coronary Artery Disease

Immune Infiltration in Atherosclerosis is Mediated by Cuproptosis-Associated Ferroptosis Genes

Novel SPECT Technologies and Approaches in Cardiac Imaging

Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life, CNKI Scholar (Chinese National Knowledge Infrastructure) and Ulrich’s web Databases.

Follow CVIA

Twitter @CVIA_JournalFacebookhttps://www.facebook.com/cvia.journal/

Loading

Metformin Treatment is Associated with Mortality in Patients with Type 2 Diabetes and Chronic Heart Failure in the Intensive Care Unit: A Retrospective Cohort Study

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Patients receiving intensive care often have diabetes mellitus (DM) together with chronic heart failure (CHF). In these patients, the use of metformin in intensive care is controversial. This study was aimed at assessing the mortality rates of patients with DM and CHF treated with metformin.

The Medical Information Mart for Intensive Care database was used to identify patients with type 2 diabetes mellitus (T2DM) and CHF. A 90-day mortality comparison was conducted between patients who were and were not administered metformin. Propensity score matching analysis and multivariable Cox proportional hazard regression were used to ensure the robustness of our results.

A total of 2153 patients (180 receiving metformin and 1973 not receiving metformin) with T2DM and CHF were included in the study. The 90-day mortality rates were 30.5% (601/1971) and 5.5% (10/182) in the non-metformin and metformin groups, respectively. In the propensity score matching analyses, metformin use was associated with a 71% lower 90-day mortality (hazard ratio, 0.29; 95% confidence interval, 0.14–0.59; P < 0.001). The results were insensitive to change when sensitivity analyses were performed.

Metformin treatment may decrease the mortality risk in critically ill patients with T2DM and CHF in the intensive care unit.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0042

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Qiao Guo, Weilong Hong and Jie Chen et al. Metformin Treatment is Associated with Mortality in Patients with Type 2 Diabetes and Chronic Heart Failure in the Intensive Care Unit: A Retrospective Cohort Study. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0042

Loading

Investigation of the Mathematical Relationship between the Aortic Valve and Aortic Root: Implications for Precise Guidance in Aortic Valve Repair

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  The study was aimed at investigating the mathematical relationship between the aortic valve and aortic root through CTA imaging-based reconstruction.

The authors of this article selected 121 healthy participants and analyzed the measurements of aortic root dimensions, including the sinotubular junction (SJT), ventriculo-arterial junction (VAJ), maximum sinus diameter (SD), sinus height (SH), effective height (eH) and coaptation height (cH). We also reconstructed 3-D aortic valve cusps using CTA imaging to calculate the aortic cusp surface areas. Data were collected to analyze the ratios and the correlation between aortic valve and aortic root dimensions.

Among healthy participants, the STJ was approximately 10% larger than the VAJ, and the SD was 1.375 times larger than the VAJ. The average eH and cH were 8.94 mm and 3.62 mm, respectively. The aortic cusp surface areas were larger in men than women. Regardless of sex, the non-coronary cusp was found to be largest, and was followed by the right coronary cusp and the left coronary cusp. Although the aortic root dimensions were also significantly larger in in men than women, the STJ to VAJ, SD to VAJ, and SH to VAJ ratios did not significantly differ by sex. The mathematical relationship between the aortic cusp surface areas and VAJ orifice area was calculated as aortic cusp surface areas

The aortic root has specific geometric ratios. The mathematical relationship between the aortic valve and aortic root might be used to guide aortic valve repair.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0044

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Luyao Ma, Kangting Tang and Guanyu Yang et al. Investigation of the Mathematical Relationship between the Aortic Valve and Aortic Root: Implications for Precise Guidance in Aortic Valve Repair. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0044

Loading

Angiotensin-converting Enzyme Inhibitors Decrease the Risk of Cardiac Rupture after Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials

Announcing a new article publication for Cardiovascular Innovations and Applications journal. ACEI therapy decreases mortality in patients with acute MI. However, the effects of ACEIs on CR are unclear.

A comprehensive search of PUBMED, EMBASE, ISI Web of Science, MEDLINE and the Cochrane Register of Controlled Trials before July 2022 was conducted to identify all RCTs on ACEIs that recorded CR as an outcome. Review Manager 5.3 was used to analyze the data.

Five RCTs including 26,383 patients with MI were identified; 71 of the 13,159 patients receiving ACEIs and 107 of the 13,224 control patients were verified to have CR. ACEI therapy started within 24 hours after the onset of acute MI significantly decreased the risk of CR, by 33% (RR: 0.67, 95% CI: 0.50–0.90, P=0.008).

Early administration of ACEIs (within 24 hours after the onset of acute MI) decrease the incidence of CR in patients with acute MI.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0040

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Siyi Li, Jinan Wang and Yan Yan et al. Angiotensin-converting Enzyme Inhibitors Decrease the Risk of Cardiac Rupture after Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0040

Loading